losartan has been researched along with Chronic Illness in 103 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 9.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital." | 9.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "No substantial differences were observed between losartan and captopril on central or regional haemodynamics, neurohormones or exercise capacity in elderly patients with stable symptomatic heart failure." | 9.09 | Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. ( Cowley, AJ; Harrison, M; Houghton, AR, 1999) |
| "The article presents data on effects of losartan (Cozaar of the Merck-Sharp-Dohme firm, USA) on neurohumoral indices in patients with mild to moderate forms of hypertension." | 9.09 | [Neurohumoral changes in patients with mild and moderate forms of hypertension under the influence of losartan]. ( Belovol, AN; Koval', SN; Masliaeva, LV; Miloslavskiĭ, DK; Mysnichenko, OV, 1999) |
| "One hundred sixty-six patients with stable heart failure in New York Heart Association functional class III or IV and an ejection fraction < or = 35% were included in a multicenter, double-blind, parallel, enalapril-controlled trial." | 9.08 | Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. ( Chang, P; Dickstein, K; Hall, C; Haunsø, S; Kjekshus, J; Remes, J; Willenheimer, R, 1995) |
| "Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK)." | 8.87 | [The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. ( Kozlovskaia, LV; Milovanov, IuS; Milovanova, LIu, 2011) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 7.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| " To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 μg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording." | 7.79 | Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. ( Cunningham, JT; Knight, WD; Mifflin, SW; Nedungadi, TP; Saxena, A; Shell, B, 2013) |
| "To evaluate the effect of angiotensin receptor blocker (losartan) on renal function during and after relief of partial unilateral ureteral obstruction (PUO)." | 7.76 | Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan). ( Abol-Enein, H; Abou-Bieh, E; Barakat, N; Mosbah, A; Shokeir, AA; Soliman, SA; Wafa, EW, 2010) |
| "Sympathetic hyperactivity and hypertension caused by chronic treatment with ouabain or sodium-rich artificial cerebrospinal fluid (aCSF) can be prevented by central administration of an angiotensin type 1 (AT(1)) receptor blocker." | 7.71 | AT(1) receptor blockers prevent sympathetic hyperactivity and hypertension by chronic ouabain and hypertonic saline. ( Leenen, FH; Zhang, J, 2001) |
| "We evaluate the acute hemodynamic and neurohormonal effects of losartan in 15 patients with symptomatic chronic heart failure (CHF), mean age 72+/-8 years, which were classified in two subgroups: (A) Patients with left ventricular ejection fraction (LVEF)< or =0." | 7.70 | Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure. ( Domínguez, J; García-Escribano, JR; Paule, A; Rodríguez-García, JL; Vázquez, M, 1999) |
| "Angiotensin converting enzyme inhibition or angiotensin II type 1 receptor antagonism can prevent and reverse insulin-induced hypertension in rats, suggesting that angiotensin II itself or an angiotensin II-dependent mechanism has an etiological influence in the pathogenesis of this hypertension model." | 7.70 | Role of angiotensin II in hyperinsulinemia-induced hypertension in rats. ( Fang, TC; Huang, WC, 1998) |
| "Treatment with losartan increased left ventricular ejection fraction (baseline vs." | 6.71 | Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure. ( Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2004) |
| " An open-label, dose-response study using subsequent 6-week treatment periods was performed in 10 nondiabetic patients with proteinuria of 5." | 6.70 | Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. ( de Jong, PE; de Zeeuw, D; Henning, RH; Laverman, GD; Navis, G, 2001) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 6.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 5.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "0] g/24 h proteinuria) were treated during 6-week periods with placebo, ARB (100 mg/d losartan), and ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide) combined with consecutively regular and low sodium diets (193 ± 62 versus 93 ± 52 mmol Na(+)/d)." | 5.15 | Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. ( Goldschmeding, R; Hemmelder, MH; Laverman, GD; Navis, G; Nguyen, TQ; Slagman, MC; Vogt, L; Waanders, F, 2011) |
| "Urinary KIM-1 level was increased in patients with nondiabetic CKD with proteinuria and decreased in parallel with proteinuria by using losartan, sodium restriction, their combination, losartan plus HCT, and the latter plus sodium restriction." | 5.14 | Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. ( Bonventre, JV; Damman, K; Hamming, I; Leuvenink, H; Navis, G; Vaidya, VS; van Goor, H; Vogt, L; Waanders, F, 2009) |
| "73 m(2) and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital." | 5.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "Japanese patients with renal insufficiency were randomly assigned to receive either an ACE inhibitor (benazepril 1." | 5.12 | A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. ( Kanno, Y; Shoda, J; Suzuki, H, 2006) |
| "This was a prospective, randomized, 9-month study of the effects of low doses of losartan (25 mg; n = 18) versus enalapril (10 mg; n = 18) versus the combination of losartan (25 mg) and enalapril (10 mg) (n = 16) on proteinuria, kidney function and metabolic profile in 54 patients with biopsy-proven chronic glomerulonephritis, hypertension and normal or slightly impaired kidney function." | 5.11 | Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. ( Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L, 2004) |
| "No substantial differences were observed between losartan and captopril on central or regional haemodynamics, neurohormones or exercise capacity in elderly patients with stable symptomatic heart failure." | 5.09 | Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly. ( Cowley, AJ; Harrison, M; Houghton, AR, 1999) |
| "The article presents data on effects of losartan (Cozaar of the Merck-Sharp-Dohme firm, USA) on neurohumoral indices in patients with mild to moderate forms of hypertension." | 5.09 | [Neurohumoral changes in patients with mild and moderate forms of hypertension under the influence of losartan]. ( Belovol, AN; Koval', SN; Masliaeva, LV; Miloslavskiĭ, DK; Mysnichenko, OV, 1999) |
| "One hundred sixty-six patients with stable heart failure in New York Heart Association functional class III or IV and an ejection fraction < or = 35% were included in a multicenter, double-blind, parallel, enalapril-controlled trial." | 5.08 | Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. ( Chang, P; Dickstein, K; Hall, C; Haunsø, S; Kjekshus, J; Remes, J; Willenheimer, R, 1995) |
| "Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK)." | 4.87 | [The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys]. ( Kozlovskaia, LV; Milovanov, IuS; Milovanova, LIu, 2011) |
| "Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)." | 4.21 | ( Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022) |
| "Chronic heart failure (CHF) increases sympathoexcitation through angiotensin II (ANG II) receptors (AT1R) in the paraventricular nucleus (PVN)." | 3.83 | Sympathoexcitation in Rats With Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus. ( Dong, Z; Huang, Q; Hultström, M; Lai, EY; Li, H; Qi, Y; Wang, H; Wang, R; Wei, X; Wilcox, CS; Wu, H; Zhou, R; Zhou, X, 2016) |
| "Modulation of vagal tone using electrical vagal nerve stimulation or pharmacological acetylcholinesterase inhibition by donepezil exerts beneficial effects in an animal model of chronic heart failure (CHF)." | 3.80 | Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure. ( Inagaki, M; Kawada, T; Li, M; Sugimachi, M; Uemura, K; Zheng, C, 2014) |
| " To test the role of the brain renin-angiotensin system (RAS) in CIH hypertension, rats were implanted with intracerebroventricular (icv) cannulae delivering losartan (1 μg/h) or vehicle (VEH) via miniosmotic pumps and telemetry devices for arterial pressure recording." | 3.79 | Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia. ( Cunningham, JT; Knight, WD; Mifflin, SW; Nedungadi, TP; Saxena, A; Shell, B, 2013) |
| "To evaluate the effect of angiotensin receptor blocker (losartan) on renal function during and after relief of partial unilateral ureteral obstruction (PUO)." | 3.76 | Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan). ( Abol-Enein, H; Abou-Bieh, E; Barakat, N; Mosbah, A; Shokeir, AA; Soliman, SA; Wafa, EW, 2010) |
| "Our data show that the effects of losartan and amlodipine on the absolute mean reduction of blood pressure and proteinuria in non-diabetic nephropathy patients are similar between the different ACE or AGT genotypes." | 3.73 | [Pharmacogenetics of angiotensin system in non diabetic nephropathy]. ( Alvarez, V; Arias, M; Campistol, JM; Coto, E; Fernández Andrade, C; Galcerán, JM; Luño, J; Marín, R; Poveda, R; Praga, M; Rivera, F; Vallés, M, 2005) |
| "Losartan could reduce pulmonary arterial collagen I expression, it may be one of the therapeutic mechanisms on hypoxic pulmonary hypertension of losartan." | 3.72 | [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]. ( Chen, XJ; Cheng, DY; Guan, J; Su, QL; Wang, H; Zhang, Y, 2004) |
| "Sympathetic hyperactivity and hypertension caused by chronic treatment with ouabain or sodium-rich artificial cerebrospinal fluid (aCSF) can be prevented by central administration of an angiotensin type 1 (AT(1)) receptor blocker." | 3.71 | AT(1) receptor blockers prevent sympathetic hyperactivity and hypertension by chronic ouabain and hypertonic saline. ( Leenen, FH; Zhang, J, 2001) |
| "CNS angiotensin II (AII) hypertension is induced by chronic, low dose intracerebroventricular (ICV) AII infusion only in rats raised on a relatively high sodium chloride diet (250 meq kg(-1)food) from weaning." | 3.70 | AT1 receptors mediate chronic central nervous system AII hypertension in rats fed high sodium chloride diet from weaning. ( Camara, AK; Osborn, JL, 1998) |
| "Angiotensin converting enzyme inhibition or angiotensin II type 1 receptor antagonism can prevent and reverse insulin-induced hypertension in rats, suggesting that angiotensin II itself or an angiotensin II-dependent mechanism has an etiological influence in the pathogenesis of this hypertension model." | 3.70 | Role of angiotensin II in hyperinsulinemia-induced hypertension in rats. ( Fang, TC; Huang, WC, 1998) |
| "We evaluate the acute hemodynamic and neurohormonal effects of losartan in 15 patients with symptomatic chronic heart failure (CHF), mean age 72+/-8 years, which were classified in two subgroups: (A) Patients with left ventricular ejection fraction (LVEF)< or =0." | 3.70 | Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure. ( Domínguez, J; García-Escribano, JR; Paule, A; Rodríguez-García, JL; Vázquez, M, 1999) |
| "In the present study, the effects of chronic hypoxia on the expression and localization of angiotensin II (Ang II) receptors are investigated by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry." | 3.70 | Chronic hypoxia upregulates the expression and function of AT(1) receptor in rat carotid body. ( Fung, ML; Lam, SY; Leung, PS, 2000) |
| "We examined the mechanisms mediating hypertension in conscious rats during acute and chronic infusion of angiotensin II (ANG II) at pressor doses (50, 100, and 200 ng." | 3.69 | Acute and chronic angiotensin hypertension: neural and nonneural components, time course, and dose dependency. ( Blaine, EH; Dale, WE; Hasser, EM; Li, Q, 1996) |
| "The etiology of CKD was type 2 diabetes mellitus in 12 and glomerulonephritis in 4 patients." | 2.71 | Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. ( Agarwal, R, 2003) |
| "Treatment with losartan increased left ventricular ejection fraction (baseline vs." | 2.71 | Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure. ( Hisatome, I; Igawa, O; Kato, M; Kinugawa, T; Ogino, K; Osaki, S; Shigemasa, C, 2004) |
| "Losartan has been shown to increase urinary uric acid excretion and hence to lower serum uric acid levels." | 2.70 | Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. ( Brunner, HR; Burnier, M; Chiolero, A; Fallab-Stubi, CL; Gerster, JC; Maillard, M; Würzner, G, 2001) |
| " An open-label, dose-response study using subsequent 6-week treatment periods was performed in 10 nondiabetic patients with proteinuria of 5." | 2.70 | Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. ( de Jong, PE; de Zeeuw, D; Henning, RH; Laverman, GD; Navis, G, 2001) |
| "The treatment with losartan significantly decreased the plasma levels of TGF-beta1 (P < 0." | 2.69 | Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. ( Campistol, JM; Clesca, PH; Iñigo, P; Jimenez, W; Lario, S; Oppenheimer, F; Rivera, F, 1999) |
| "Thus, strategies for the treatment of heart failure have focused on agents that block the RAS." | 2.44 | Anti-angiotensin therapy: new perspectives. ( Deswal, A; Mann, DL; Ramasubbu, K, 2007) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | 2.43 | Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006) |
| "Vitamin D deficiency is associated with pulmonary fibrosis and impaired lung function, but the underlying mechanism has not yet been fully elucidated." | 1.46 | Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system. ( Fu, J; Liu, T; Shi, Y; Xing, Y; Xue, X; Yao, L; Zhao, X, 2017) |
| "Thus, the dehydration-induced switch in control of tSNA from hypothalamus to cNTS seems to be mediated via activation of AP1 transcription factors in the cNTS." | 1.37 | Switching control of sympathetic activity from forebrain to hindbrain in chronic dehydration. ( Antunes, VR; Colombari, DS; Colombari, E; Ferguson, AV; Freiria-Oliveira, AH; Fry, M; Hindmarch, C; Murphy, D; Paton, JF; Yao, ST, 2011) |
| "While proteinuria was reduced in all four of these patients by 45, 96, 53, and 64%, respectively, three patients experienced side effects requiring changes in the aliskiren dose." | 1.37 | Are we ready to use aliskiren in children? ( Filler, G; Kelland, EE; McAuley, LM, 2011) |
| "Nifedipine-treated animals displayed hemodynamics, LV dilatation, hypertrophy, and loss of function similar to those of the untreated group." | 1.35 | Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation. ( Arsenault, M; Beaudoin, J; Champetier, S; Couet, J; Lachance, D; Plante, E; Roussel, E, 2009) |
| " To test this hypothesis, we have used a novel approach to effectively "clamp" the sympathetic nervous system at a fixed level through chronic administration of the ganglionic blocking agent hexamethonium (15 mg/kg/h) and the alpha agonist phenylephrine (2." | 1.33 | Role of a responsive sympathetic nervous system in the chronic hypotensive effects of losartan in normal rats. ( Collister, JP; Osborn, JW, 2005) |
| "Losartan (10 mg/kg) was given daily by gavage to Losartan (L) and Losartan + Chronic Stress (L+CS) groups." | 1.32 | Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress. ( Erbas, B; Gürol, AO; Ozek, M; Ozkök, E; Uresin, Y, 2004) |
| "Losartan treatment was started when serum creatinine rose above 4." | 1.31 | Progression of renal failure delayed by use of losartan in a case of IgA nephropathy. ( Iseki, K; Takishita, S, 2002) |
| "Losartan-treated rats showed reduced tail pressure (104+/-3 versus 117+/-3 mm Hg in the vehicle group)." | 1.30 | Chronic AT1 receptor blockade alters aortic nerve activity in hypertension. ( dos Santos, CM; Krieger, EM; Michelini, LC; Moreira, ED, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (19.42) | 18.2507 |
| 2000's | 55 (53.40) | 29.6817 |
| 2010's | 27 (26.21) | 24.3611 |
| 2020's | 1 (0.97) | 2.80 |
| Authors | Studies |
|---|---|
| Nese, M | 1 |
| Riboli, G | 1 |
| Brighetti, G | 1 |
| Sassi, V | 1 |
| Camela, E | 1 |
| Caselli, G | 1 |
| Sassaroli, S | 1 |
| Borlimi, R | 1 |
| Aucoin, M | 1 |
| Cooley, K | 1 |
| Saunders, PR | 1 |
| Carè, J | 1 |
| Anheyer, D | 1 |
| Medina, DN | 1 |
| Cardozo, V | 1 |
| Remy, D | 1 |
| Hannan, N | 1 |
| Garber, A | 1 |
| Velayos, M | 1 |
| Muñoz-Serrano, AJ | 1 |
| Estefanía-Fernández, K | 1 |
| Sarmiento Caldas, MC | 1 |
| Moratilla Lapeña, L | 1 |
| López-Santamaría, M | 1 |
| López-Gutiérrez, JC | 1 |
| Li, J | 2 |
| Zhang, J | 2 |
| Shen, S | 1 |
| Zhang, B | 2 |
| Yu, WW | 1 |
| Toyoda, H | 1 |
| Huang, DQ | 1 |
| Le, MH | 1 |
| Nguyen, MH | 1 |
| Huang, R | 1 |
| Zhu, L | 1 |
| Wang, J | 6 |
| Xue, L | 1 |
| Liu, L | 2 |
| Yan, X | 2 |
| Huang, S | 1 |
| Li, Y | 6 |
| Xu, T | 1 |
| Li, C | 3 |
| Ji, F | 1 |
| Ming, F | 1 |
| Zhao, Y | 2 |
| Cheng, J | 1 |
| Wang, Y | 5 |
| Zhao, H | 1 |
| Hong, S | 1 |
| Chen, K | 2 |
| Zhao, XA | 1 |
| Zou, L | 1 |
| Sang, D | 1 |
| Shao, H | 1 |
| Guan, X | 1 |
| Chen, X | 2 |
| Chen, Y | 4 |
| Wei, J | 1 |
| Zhu, C | 1 |
| Wu, C | 1 |
| Moore, HB | 1 |
| Barrett, CD | 1 |
| Moore, EE | 1 |
| Jhunjhunwala, R | 1 |
| McIntyre, RC | 1 |
| Moore, PK | 1 |
| Hajizadeh, N | 1 |
| Talmor, DS | 1 |
| Sauaia, A | 1 |
| Yaffe, MB | 1 |
| Liu, C | 3 |
| Lin, Y | 1 |
| Dong, Y | 1 |
| Wu, Y | 1 |
| Bao, Y | 1 |
| Yan, H | 2 |
| Ma, J | 1 |
| Fernández-Cuadros, ME | 1 |
| Albaladejo-Florín, MJ | 1 |
| Álava-Rabasa, S | 1 |
| Usandizaga-Elio, I | 1 |
| Martinez-Quintanilla Jimenez, D | 1 |
| Peña-Lora, D | 1 |
| Neira-Borrajo, I | 1 |
| López-Muñoz, MJ | 1 |
| Rodríguez-de-Cía, J | 1 |
| Pérez-Moro, OS | 1 |
| Abdallah, M | 1 |
| Alsaleh, H | 1 |
| Baradwan, A | 1 |
| Alfawares, R | 1 |
| Alobaid, A | 1 |
| Rasheed, A | 1 |
| Soliman, I | 1 |
| Wendel Garcia, PD | 1 |
| Fumeaux, T | 1 |
| Guerci, P | 1 |
| Heuberger, DM | 1 |
| Montomoli, J | 2 |
| Roche-Campo, F | 1 |
| Schuepbach, RA | 1 |
| Hilty, MP | 1 |
| Poloni, TE | 1 |
| Carlos, AF | 1 |
| Cairati, M | 1 |
| Cutaia, C | 1 |
| Medici, V | 1 |
| Marelli, E | 1 |
| Ferrari, D | 1 |
| Galli, A | 1 |
| Bognetti, P | 1 |
| Davin, A | 1 |
| Cirrincione, A | 1 |
| Ceretti, A | 1 |
| Cereda, C | 1 |
| Ceroni, M | 1 |
| Tronconi, L | 1 |
| Vitali, S | 1 |
| Guaita, A | 1 |
| Leeds, JS | 1 |
| Raviprakash, V | 1 |
| Jacques, T | 1 |
| Scanlon, N | 1 |
| Cundall, J | 1 |
| Leeds, CM | 1 |
| Riva, A | 1 |
| Gray, EH | 1 |
| Azarian, S | 1 |
| Zamalloa, A | 1 |
| McPhail, MJW | 1 |
| Vincent, RP | 1 |
| Williams, R | 1 |
| Chokshi, S | 1 |
| Patel, VC | 1 |
| Edwards, LA | 1 |
| Alqarawi, W | 1 |
| Birnie, DH | 1 |
| Golian, M | 1 |
| Nair, GM | 1 |
| Nery, PB | 1 |
| Klein, A | 1 |
| Davis, DR | 1 |
| Sadek, MM | 1 |
| Neilipovitz, D | 1 |
| Johnson, CB | 1 |
| Green, MS | 1 |
| Redpath, C | 1 |
| Miller, DC | 1 |
| Beamer, P | 1 |
| Billheimer, D | 1 |
| Subbian, V | 1 |
| Sorooshian, A | 1 |
| Campbell, BS | 1 |
| Mosier, JM | 1 |
| Novaretti, JV | 1 |
| Astur, DC | 1 |
| Cavalcante, ELB | 1 |
| Kaleka, CC | 1 |
| Amaro, JT | 1 |
| Cohen, M | 1 |
| Huang, W | 1 |
| Li, T | 1 |
| Ling, Y | 1 |
| Qian, ZP | 1 |
| Zhang, YY | 1 |
| Huang, D | 1 |
| Xu, SB | 1 |
| Liu, XH | 1 |
| Xia, L | 1 |
| Yang, Y | 3 |
| Lu, SH | 1 |
| Lu, HZ | 1 |
| Zhang, R | 2 |
| Ma, JX | 1 |
| Tang, S | 1 |
| Li, CM | 1 |
| Wan, J | 1 |
| Wang, JF | 1 |
| Ma, JQ | 1 |
| Luo, JJ | 1 |
| Chen, HY | 2 |
| Mi, SL | 1 |
| Chen, SY | 1 |
| Su, YG | 1 |
| Ge, JB | 1 |
| Milheiro, SA | 1 |
| Gonçalves, J | 1 |
| Lopes, RMRM | 1 |
| Madureira, M | 1 |
| Lobo, L | 1 |
| Lopes, A | 1 |
| Nogueira, F | 1 |
| Fontinha, D | 1 |
| Prudêncio, M | 1 |
| M Piedade, MF | 1 |
| Pinto, SN | 1 |
| Florindo, PR | 1 |
| Moreira, R | 1 |
| Castillo-Lora, J | 1 |
| Delley, MF | 1 |
| Laga, SM | 1 |
| Mayer, JM | 1 |
| Sutjarit, N | 1 |
| Thongon, N | 1 |
| Weerachayaphorn, J | 1 |
| Piyachaturawat, P | 1 |
| Suksamrarn, A | 1 |
| Suksen, K | 1 |
| Papachristou, DJ | 1 |
| Blair, HC | 1 |
| Hu, Y | 1 |
| Shen, P | 1 |
| Zeng, N | 1 |
| Wang, L | 3 |
| Yan, D | 1 |
| Cui, L | 1 |
| Yang, K | 2 |
| Zhai, C | 1 |
| Yang, M | 1 |
| Lao, X | 1 |
| Sun, J | 1 |
| Ma, N | 1 |
| Wang, S | 1 |
| Ye, W | 1 |
| Guo, P | 1 |
| Rahimi, S | 1 |
| Singh, MP | 1 |
| Gupta, J | 1 |
| Nakanishi, I | 1 |
| Ohkubo, K | 1 |
| Shoji, Y | 1 |
| Fujitaka, Y | 1 |
| Shimoda, K | 1 |
| Matsumoto, KI | 1 |
| Fukuhara, K | 1 |
| Hamada, H | 1 |
| van der Boom, T | 1 |
| Gruppen, EG | 1 |
| Lefrandt, JD | 1 |
| Connelly, MA | 1 |
| Links, TP | 1 |
| Dullaart, RPF | 1 |
| Berry, JD | 1 |
| Bedlack, R | 1 |
| Mathews, D | 1 |
| Agnese, W | 1 |
| Apple, S | 1 |
| Meloncelli, S | 1 |
| Divizia, M | 1 |
| Germani, G | 1 |
| Adefegha, SA | 1 |
| Bottari, NB | 1 |
| Leal, DB | 1 |
| de Andrade, CM | 1 |
| Schetinger, MR | 1 |
| Martínez-Velasco, A | 1 |
| Perez-Ortiz, AC | 1 |
| Antonio-Aguirre, B | 1 |
| Martínez-Villaseñor, L | 1 |
| Lira-Romero, E | 1 |
| Palacio-Pastrana, C | 1 |
| Zenteno, JC | 1 |
| Ramirez, I | 1 |
| Zepeda-Palacio, C | 1 |
| Mendoza-Velásquez, C | 1 |
| Camacho-Ordóñez, A | 1 |
| Ortiz Bibriesca, DM | 1 |
| Estrada-Mena, FJ | 1 |
| Martin, BL | 1 |
| Thompson, LC | 1 |
| Kim, YH | 2 |
| Snow, SJ | 1 |
| Schladweiler, MC | 1 |
| Phillips, P | 1 |
| Harmon, M | 1 |
| King, C | 1 |
| Richards, J | 1 |
| George, I | 1 |
| Haykal-Coates, N | 1 |
| Gilmour, MI | 1 |
| Kodavanti, UP | 1 |
| Hazari, MS | 1 |
| Farraj, AK | 1 |
| Shen, Z | 1 |
| Zou, Y | 1 |
| Gao, K | 1 |
| Lazar, S | 1 |
| Wurtzel, JGT | 1 |
| Ma, P | 1 |
| Goldfinger, LE | 1 |
| Vukelic, M | 1 |
| Laloo, A | 1 |
| Kyttaris, VC | 1 |
| Chen, R | 1 |
| Chen, J | 2 |
| Xun, J | 1 |
| Hu, Z | 1 |
| Huang, Q | 3 |
| Steinhart, C | 1 |
| Shen, Y | 1 |
| Lu, H | 1 |
| Mansuri, A | 1 |
| Lokhande, K | 1 |
| Kore, S | 1 |
| Gaikwad, S | 1 |
| Nawani, N | 1 |
| Swamy, KV | 1 |
| Junnarkar, M | 1 |
| Pawar, S | 1 |
| Shaheen, MY | 1 |
| Basudan, AM | 1 |
| Niazy, AA | 1 |
| van den Beucken, JJJP | 1 |
| Jansen, JA | 1 |
| Alghamdi, HS | 1 |
| Gao, Q | 2 |
| Guo, X | 1 |
| Cao, Y | 1 |
| Jia, X | 1 |
| Xu, S | 1 |
| Lu, C | 2 |
| Zhu, H | 2 |
| Melku, M | 1 |
| Abebe, G | 1 |
| Teketel, A | 1 |
| Asrie, F | 1 |
| Yalew, A | 1 |
| Biadgo, B | 1 |
| Kassa, E | 1 |
| Damtie, D | 1 |
| Anlay, DZ | 1 |
| Ahmed, MFE | 1 |
| Ramadan, H | 1 |
| Seinige, D | 1 |
| Kehrenberg, C | 1 |
| Abd El-Wahab, A | 1 |
| Volkmann, N | 1 |
| Kemper, N | 1 |
| Schulz, J | 1 |
| Hu, MY | 1 |
| Wu, YN | 1 |
| McEvoy, MP | 1 |
| Wang, YF | 1 |
| Cong, WL | 1 |
| Liu, LP | 1 |
| Li, XX | 1 |
| Zhou, CL | 1 |
| Chen, WM | 1 |
| Wei, KL | 1 |
| Tung, SY | 1 |
| Shen, CH | 1 |
| Chang, TS | 1 |
| Yen, CW | 1 |
| Hsieh, YY | 1 |
| Chiu, WN | 1 |
| Hu, JH | 1 |
| Lu, SN | 1 |
| Hung, CH | 1 |
| Alakavuklar, MA | 1 |
| Fuqua, C | 1 |
| Luo, KL | 1 |
| Underwood, RS | 1 |
| Greenwald, I | 1 |
| Elashiry, MM | 1 |
| Elashiry, M | 1 |
| Zeitoun, R | 1 |
| Elsayed, R | 1 |
| Tian, F | 1 |
| Saber, SE | 1 |
| Elashry, SH | 1 |
| Tay, FR | 1 |
| Cutler, CW | 1 |
| O'Dowd, A | 1 |
| Maciel, M | 1 |
| Poole, ST | 1 |
| Jobling, MG | 1 |
| Rollenhagen, JE | 1 |
| Woods, CM | 1 |
| Sincock, SA | 1 |
| McVeigh, AL | 1 |
| Gregory, MJ | 1 |
| Maves, RC | 1 |
| Prouty, MG | 1 |
| Holmes, RK | 1 |
| Savarino, SJ | 1 |
| Mor, MK | 1 |
| Palevsky, PM | 1 |
| Kaufman, JS | 1 |
| Thiessen Philbrook, H | 1 |
| Weisbord, SD | 1 |
| Parikh, CR | 1 |
| John, CM | 1 |
| Phillips, NJ | 1 |
| Jarvis, GA | 1 |
| Zhu, Y | 1 |
| Kilburn, S | 1 |
| Kapoor, M | 1 |
| Chaturvedi, S | 1 |
| Shaw, KJ | 1 |
| Chaturvedi, V | 1 |
| Kong, X | 1 |
| Zhang, T | 1 |
| Xiao, H | 1 |
| Feng, X | 1 |
| Tu, H | 2 |
| Feng, J | 1 |
| Sabet, M | 1 |
| Tarazi, Z | 1 |
| Griffith, DC | 1 |
| Nguyen, F | 1 |
| Guan, P | 1 |
| Guerrero, DT | 1 |
| Kolla, V | 1 |
| Naraparaju, K | 1 |
| Perry, LM | 1 |
| Soberman, D | 1 |
| Pressly, BB | 1 |
| Alferiev, IS | 1 |
| Chorny, M | 1 |
| Brodeur, GM | 1 |
| Gao, X | 2 |
| Cheng, YH | 1 |
| Enten, GA | 1 |
| DeSantis, AJ | 1 |
| Gaponenko, V | 1 |
| Majetschak, M | 1 |
| Kim, DY | 1 |
| Choi, MJ | 1 |
| Ko, TK | 1 |
| Lee, NH | 1 |
| Kim, OH | 1 |
| Cheon, HG | 1 |
| Cai, H | 1 |
| Yip, V | 1 |
| Lee, MV | 1 |
| Wong, S | 1 |
| Saad, O | 1 |
| Ma, S | 1 |
| Ljumanovic, N | 1 |
| Khojasteh, SC | 1 |
| Kamath, AV | 1 |
| Shen, BQ | 1 |
| Cuypers, ML | 1 |
| Chanteux, H | 1 |
| Gillent, E | 1 |
| Bonnaillie, P | 1 |
| Saunders, K | 1 |
| Beckers, C | 1 |
| Delatour, C | 1 |
| Dell'Aiera, S | 1 |
| Ungell, AL | 1 |
| Nicolaï, J | 1 |
| Knapp, AK | 1 |
| Chen, A | 1 |
| Griffin-Nolan, RJ | 1 |
| Baur, LE | 1 |
| Carroll, CJW | 1 |
| Gray, JE | 1 |
| Hoffman, AM | 1 |
| Li, X | 4 |
| Post, AK | 1 |
| Slette, IJ | 1 |
| Collins, SL | 1 |
| Luo, Y | 1 |
| Smith, MD | 1 |
| Temitayo, GI | 1 |
| Olawande, B | 1 |
| Emmanuel, YO | 1 |
| Timothy, AT | 1 |
| Kehinde, O | 1 |
| Susan, LF | 1 |
| Ezra, L | 1 |
| Joseph, OO | 1 |
| Lev, S | 1 |
| Desmarini, D | 1 |
| Liuwantara, D | 1 |
| Sorrell, TC | 1 |
| Hawthorne, WJ | 1 |
| Djordjevic, JT | 1 |
| Verso, MG | 1 |
| Costantino, C | 1 |
| Marrella, A | 1 |
| Immordino, P | 1 |
| Vitale, F | 1 |
| Amodio, E | 1 |
| Wang, YD | 1 |
| Yao, WL | 1 |
| Xin, ZM | 1 |
| Han, TT | 1 |
| Wang, ZG | 1 |
| Chen, L | 1 |
| Cai, C | 1 |
| Zhang, Y | 6 |
| Ba, D | 1 |
| Wen, S | 1 |
| Tian, Q | 1 |
| Lv, W | 1 |
| Cheng, G | 1 |
| Li, N | 1 |
| Yue, XY | 1 |
| Chu, WJ | 1 |
| Chen, Q | 1 |
| Choi, ES | 1 |
| Zhao, X | 4 |
| Zhou, HD | 1 |
| Sun, XF | 1 |
| Sharma, S | 2 |
| Chhoker, S | 1 |
| Xie, C | 1 |
| Ong, EWY | 1 |
| Tan, ZK | 1 |
| Evans, S | 1 |
| Weinheimer, CJ | 1 |
| Kovacs, A | 1 |
| Williams, JW | 1 |
| Randolph, GJ | 1 |
| Jiang, W | 1 |
| Barger, PM | 1 |
| Mann, DL | 2 |
| Liu, J | 3 |
| Huang, Y | 1 |
| Kong, L | 1 |
| Yu, X | 1 |
| Feng, B | 1 |
| Liu, D | 1 |
| Zhao, B | 1 |
| Mendes, GC | 1 |
| Yuan, P | 1 |
| Ge, D | 1 |
| Wang, WM | 1 |
| Fontes, EPB | 1 |
| Li, P | 1 |
| Shan, L | 1 |
| He, P | 1 |
| Katoh, T | 1 |
| Sengoku, T | 1 |
| Hirata, K | 1 |
| Ogata, K | 1 |
| Suga, H | 1 |
| Shun, C | 1 |
| Yong-Yi, J | 1 |
| Mei-Li, C | 1 |
| Shi-Li, L | 1 |
| Jian-Bo, Z | 1 |
| Dan-Li, W | 1 |
| Zhi-Min, G | 1 |
| Ibrahim, AM | 1 |
| Zakhary, SY | 1 |
| Amin, SAW | 1 |
| Ugurlu, M | 1 |
| Fornari, VJ | 1 |
| Hartmann, MSM | 1 |
| Vanni, JR | 1 |
| Rodriguez, R | 1 |
| Langaro, MC | 1 |
| Pelepenko, LE | 1 |
| Zaia, AA | 1 |
| Nakanjako, D | 1 |
| Zalwango, F | 1 |
| Wairagala, P | 1 |
| Luboga, F | 1 |
| Andia Biraro, I | 1 |
| Bukirwa, VD | 1 |
| Mboowa, MG | 1 |
| Cose, S | 1 |
| Seeley, J | 1 |
| Elliott, A | 1 |
| Zhao, G | 1 |
| Sun, P | 1 |
| Hao, S | 1 |
| Wang, X | 1 |
| Qu, G | 1 |
| Xing, Y | 2 |
| Xu, X | 1 |
| Maierhofer, M | 1 |
| Rieger, V | 1 |
| Mayr, T | 1 |
| Liu, Y | 3 |
| Zhang, Q | 1 |
| Bigliardi, AP | 1 |
| Fernandes, CLF | 1 |
| Pinto, EA | 1 |
| Dos Santos, M | 1 |
| Garcia, EM | 1 |
| Baisch, PRM | 1 |
| Soares, MCF | 1 |
| Muccillo-Baisch, AL | 1 |
| da Silva Júnior, FMR | 1 |
| Yu, W | 1 |
| Ju, C | 1 |
| Wang, K | 1 |
| Zheng, Z | 1 |
| Liu, H | 1 |
| Gao, Y | 1 |
| Martínez-Navarro, EM | 1 |
| Cebrián-Tarancón, C | 1 |
| Moratalla-López, N | 1 |
| Lorenzo, C | 1 |
| Alonso, GL | 1 |
| Salinas, RM | 1 |
| Bermúdez de Castro, JM | 1 |
| Modesto-Mata, M | 1 |
| Martín-Francés, L | 1 |
| García-Campos, C | 1 |
| Martínez de Pinillos, M | 1 |
| Martinón-Torres, M | 1 |
| Hasani, M | 1 |
| Wu, F | 2 |
| Warriner, K | 1 |
| Kurz, M | 1 |
| Gretzke, D | 1 |
| Hörlein, R | 1 |
| Turpault, S | 1 |
| Atzrodt, J | 1 |
| Derdau, V | 1 |
| Yao, Y | 1 |
| Ou, X | 1 |
| Zhao, S | 1 |
| Tian, B | 1 |
| Jin, S | 1 |
| Jiang, Z | 1 |
| Zhou, Z | 1 |
| Liu, M | 2 |
| Jiang, GD | 1 |
| Mou, LH | 1 |
| Chen, JJ | 1 |
| Li, ZY | 1 |
| He, SG | 1 |
| Reale, E | 1 |
| Fustinoni, S | 1 |
| Mercadante, R | 1 |
| Polledri, E | 1 |
| Hopf, NB | 1 |
| Grant, PC | 1 |
| Levy, K | 1 |
| Lattimer, TA | 1 |
| Depner, RM | 1 |
| Kerr, CW | 1 |
| Sato, J | 1 |
| Merenda, MEZ | 1 |
| Uemoto, AT | 1 |
| Dos Santos, MP | 1 |
| Barion, MRL | 1 |
| Carciofi, AC | 1 |
| de Paula Dorigam, JC | 1 |
| Ribeiro, LB | 1 |
| Vasconcellos, RS | 1 |
| Waller, SB | 1 |
| Peter, CM | 1 |
| Hoffmann, JF | 1 |
| Cleff, MB | 1 |
| Faria de, RO | 1 |
| Zani, JL | 1 |
| Martins, BA | 1 |
| Sande, D | 1 |
| Solares, MD | 1 |
| Takahashi, JA | 1 |
| Yang, S | 2 |
| Jia, Y | 1 |
| Yin, C | 1 |
| Zhao, R | 1 |
| Ojha, M | 1 |
| Wu, B | 1 |
| Deepa, M | 1 |
| Mo, J | 1 |
| Au, DW | 1 |
| Wan, MT | 1 |
| Shi, J | 1 |
| Zhang, G | 1 |
| Winkler, C | 1 |
| Kong, RY | 1 |
| Seemann, F | 1 |
| Bianco, M | 1 |
| Calvano, CD | 1 |
| Ventura, G | 1 |
| Bianco, G | 1 |
| Losito, I | 1 |
| Cataldi, TRI | 1 |
| Angiolella, L | 1 |
| Staudt, A | 1 |
| Duarte, PF | 1 |
| Amaral, BPD | 1 |
| Peixoto Andrade, BCO | 1 |
| Simas, NK | 1 |
| Correa Ramos Leal, I | 1 |
| Sangenito, LS | 1 |
| Santos, ALSD | 1 |
| de Oliveira, D | 1 |
| Junges, A | 1 |
| Cansian, RL | 1 |
| Paroul, N | 1 |
| Siu, J | 1 |
| Klingler, L | 1 |
| Hung, CT | 1 |
| Jeong, SH | 1 |
| Smith, S | 1 |
| Tingle, MD | 1 |
| Wagner Mackenzie, B | 1 |
| Biswas, K | 1 |
| Douglas, RG | 1 |
| Oza, AM | 1 |
| Lorusso, D | 1 |
| Aghajanian, C | 1 |
| Oaknin, A | 1 |
| Dean, A | 1 |
| Colombo, N | 1 |
| Weberpals, JI | 1 |
| Clamp, AR | 1 |
| Scambia, G | 1 |
| Leary, A | 1 |
| Holloway, RW | 1 |
| Gancedo, MA | 1 |
| Fong, PC | 1 |
| Goh, JC | 1 |
| O'Malley, DM | 1 |
| Armstrong, DK | 1 |
| Banerjee, S | 1 |
| García-Donas, J | 1 |
| Swisher, EM | 1 |
| Cella, D | 1 |
| Meunier, J | 1 |
| Goble, S | 1 |
| Cameron, T | 1 |
| Maloney, L | 1 |
| Mörk, AC | 1 |
| Bedel, J | 1 |
| Ledermann, JA | 1 |
| Coleman, RL | 1 |
| Vlek, SL | 1 |
| Burm, R | 1 |
| Govers, TM | 1 |
| Vleugels, MPH | 1 |
| Tuynman, JB | 1 |
| Mijatovic, V | 1 |
| Leicht, AS | 1 |
| Connor, J | 1 |
| Conduit, N | 1 |
| Vaquera, A | 1 |
| Gómez, MA | 1 |
| McKay, JA | 1 |
| Church, AL | 1 |
| Rubin, N | 1 |
| Emory, TH | 1 |
| Hoven, NF | 1 |
| Kuehn-Hajder, JE | 1 |
| Nelson, MT | 1 |
| Ramanna, S | 1 |
| Auerbach, EJ | 1 |
| Moeller, S | 1 |
| Bolan, PJ | 1 |
| Fox, NP | 1 |
| Leonard, M | 1 |
| Sjerps, MJ | 1 |
| Chang, EF | 1 |
| Hyun, S | 1 |
| Saejio, A | 1 |
| Shanmugam, S | 1 |
| Liu, X | 2 |
| Sun, M | 1 |
| Bai, Z | 1 |
| Jaque-Fernandez, F | 1 |
| Beaulant, A | 1 |
| Berthier, C | 1 |
| Monteiro, L | 1 |
| Allard, B | 1 |
| Casas, M | 1 |
| Rieusset, J | 1 |
| Jacquemond, V | 1 |
| Góngora-García, OR | 1 |
| Aca-Aca, G | 1 |
| Baz-Rodríguez, SA | 1 |
| Monte, A | 1 |
| Maganaris, C | 1 |
| Baltzopoulos, V | 1 |
| Zamparo, P | 1 |
| Wang, Z | 2 |
| Hou, Y | 1 |
| Cai, L | 1 |
| Tu, YJ | 1 |
| Tan, B | 1 |
| Jiang, L | 1 |
| Wu, ZH | 1 |
| Yu, HJ | 1 |
| Li, XQ | 1 |
| Yang, AD | 1 |
| Titze, IR | 1 |
| Palaparthi, A | 1 |
| Mau, T | 1 |
| González, MA | 1 |
| Goiri, F | 1 |
| Barandika, JF | 1 |
| García-Pérez, AL | 1 |
| Jatt, LP | 1 |
| Gandhi, MM | 1 |
| Guo, R | 1 |
| Sukhija-Cohen, A | 1 |
| Bhattacharya, D | 1 |
| Tseng, CH | 1 |
| Chew, KW | 1 |
| Onwumere, J | 1 |
| Pia Tek, J | 1 |
| Budnyak, T | 1 |
| Budnyk, S | 1 |
| Karim, Z | 1 |
| Thersleff, T | 1 |
| Kuśtrowski, P | 1 |
| Mathew, AP | 1 |
| Slabon, A | 1 |
| Guo, M | 1 |
| Zhao, T | 1 |
| Xing, Z | 1 |
| Qiu, Y | 1 |
| Pan, K | 1 |
| Li, Z | 2 |
| Zhou, W | 1 |
| Ghassemi Tabrizi, S | 1 |
| Arbuznikov, AV | 1 |
| Jiménez-Hoyos, CA | 1 |
| Kaupp, M | 1 |
| Lin, MH | 2 |
| Bulman, DM | 1 |
| Remucal, CK | 1 |
| Chaplin, BP | 1 |
| Laguerre, A | 1 |
| George, LA | 1 |
| Gall, ET | 1 |
| Emerson, MS | 1 |
| Wang, H | 6 |
| Maginn, EJ | 1 |
| Margulis, CJ | 1 |
| Li, H | 3 |
| Feng, W | 1 |
| Kang, X | 2 |
| Yan, S | 1 |
| Chao, M | 1 |
| Mo, S | 1 |
| Sun, W | 1 |
| Lu, Y | 1 |
| Chen, C | 1 |
| Stevens, DM | 1 |
| Adiseshaiah, P | 1 |
| Dasa, SSK | 1 |
| Potter, TM | 1 |
| Skoczen, SL | 1 |
| Snapp, KS | 1 |
| Cedrone, E | 1 |
| Patel, N | 1 |
| Busman-Sahay, K | 1 |
| Rosen, EP | 1 |
| Sykes, C | 1 |
| Cottrell, M | 1 |
| Dobrovolskaia, MA | 1 |
| Estes, JD | 1 |
| Kashuba, ADM | 1 |
| Stern, ST | 1 |
| Özütemiz, C | 1 |
| Neil, EC | 1 |
| Tanwar, M | 1 |
| Rubin, NT | 1 |
| Ozturk, K | 1 |
| Cayci, Z | 1 |
| Duscha, BD | 1 |
| Kraus, WE | 1 |
| Jones, WS | 1 |
| Robbins, JL | 1 |
| Piner, LW | 1 |
| Huffman, KM | 1 |
| Allen, JD | 1 |
| Annex, BH | 1 |
| Mehmood, T | 1 |
| Ahmad, I | 1 |
| Bibi, S | 1 |
| Mustafa, B | 1 |
| Ali, I | 1 |
| Dahal, RH | 1 |
| Chaudhary, DK | 1 |
| Kim, DU | 1 |
| Kim, J | 2 |
| Yeter, HH | 1 |
| Gonul, I | 1 |
| Guz, G | 1 |
| Helvaci, O | 1 |
| Korucu, B | 1 |
| Akcay, OF | 1 |
| Derici, U | 1 |
| Arinsoy, T | 1 |
| Neffati, R | 1 |
| Judeinstein, P | 1 |
| Rault, J | 1 |
| Xu, Y | 1 |
| Chai, X | 1 |
| Ren, T | 1 |
| Yu, S | 1 |
| Fu, Q | 2 |
| Ye, J | 1 |
| Ge, X | 1 |
| Song, J | 1 |
| Yang, H | 3 |
| El-Baba, TJ | 1 |
| Lutomski, CA | 1 |
| Kantsadi, AL | 1 |
| Malla, TR | 1 |
| John, T | 1 |
| Mikhailov, V | 1 |
| Bolla, JR | 1 |
| Schofield, CJ | 1 |
| Zitzmann, N | 1 |
| Vakonakis, I | 1 |
| Robinson, CV | 1 |
| Langham, MC | 1 |
| Caporale, AS | 1 |
| Wehrli, FW | 1 |
| Parry, S | 1 |
| Schwartz, N | 1 |
| den Boer, RB | 1 |
| Jones, KI | 1 |
| Ash, S | 1 |
| van Boxel, GI | 1 |
| Gillies, RS | 1 |
| O'Donnell, T | 1 |
| Ruurda, JP | 1 |
| Sgromo, B | 1 |
| Silva, MA | 1 |
| Maynard, ND | 1 |
| Sivieri, EM | 1 |
| Eichenwald, EC | 1 |
| Rub, D | 1 |
| Abbasi, S | 1 |
| Krahnert, I | 1 |
| Bolze, A | 1 |
| Gibon, Y | 1 |
| Fernie, AR | 1 |
| Huang, L | 1 |
| Wan, Y | 1 |
| Dang, Z | 1 |
| Yang, P | 1 |
| Yang, Q | 1 |
| Wu, S | 2 |
| Lin, CC | 1 |
| Hsu, CT | 1 |
| Liu, W | 2 |
| Huang, SC | 1 |
| Kortz, U | 1 |
| Mougharbel, AS | 1 |
| Chen, TY | 1 |
| Hu, CW | 1 |
| Lee, JF | 1 |
| Wang, CC | 1 |
| Liao, YF | 1 |
| Li, LJ | 1 |
| Li, L | 1 |
| Peng, S | 1 |
| Stimming, U | 1 |
| Hebbar Kannur, K | 1 |
| Yaqub, TB | 1 |
| Pupier, C | 1 |
| Héau, C | 1 |
| Cavaleiro, A | 1 |
| Yamamoto, S | 1 |
| Ono, A | 1 |
| Matsui, J | 1 |
| Hoshino, N | 1 |
| Akutagawa, T | 1 |
| Miyashita, T | 1 |
| Mitsuishi, M | 1 |
| Patel, SM | 1 |
| Smith, TG | 1 |
| Morton, M | 1 |
| Stiers, KM | 1 |
| Seravalli, J | 1 |
| Mayclin, SJ | 1 |
| Edwards, TE | 1 |
| Tanner, JJ | 1 |
| Becker, DF | 1 |
| Butcher, TW | 1 |
| Yang, JL | 1 |
| Hartwig, JF | 1 |
| Yu, MF | 1 |
| Xia, ZZ | 1 |
| Yao, JC | 1 |
| Feng, Z | 1 |
| Li, DH | 1 |
| Liu, T | 2 |
| Cheng, GJ | 1 |
| He, DL | 1 |
| Li, XH | 1 |
| Huurman, R | 1 |
| Schinkel, AFL | 1 |
| de Jong, PL | 1 |
| van Slegtenhorst, MA | 1 |
| Hirsch, A | 1 |
| Michels, M | 1 |
| Kataja, A | 1 |
| Tarvasmäki, T | 1 |
| Lassus, J | 1 |
| Sionis, A | 1 |
| Mebazaa, A | 1 |
| Pulkki, K | 1 |
| Banaszewski, M | 1 |
| Carubelli, V | 1 |
| Hongisto, M | 1 |
| Jankowska, E | 1 |
| Jurkko, R | 1 |
| Jäntti, T | 1 |
| Kasztura, M | 1 |
| Parissis, J | 1 |
| Sabell, T | 1 |
| Silva-Cardoso, J | 1 |
| Spinar, J | 1 |
| Tolppanen, H | 1 |
| Harjola, VP | 1 |
| Carsetti, A | 1 |
| Damiani, E | 1 |
| Casarotta, E | 1 |
| Scorcella, C | 1 |
| Domizi, R | 1 |
| Gasparri, F | 1 |
| Gabbanelli, V | 1 |
| Pantanetti, S | 1 |
| Carozza, R | 1 |
| Adrario, E | 1 |
| Donati, A | 1 |
| Almada, E | 1 |
| Pariani, A | 1 |
| Rivabella Maknis, T | 1 |
| Hidalgo, F | 1 |
| Vena, R | 1 |
| Favre, C | 1 |
| Larocca, MC | 1 |
| Lu, ZY | 1 |
| Jiang, WD | 1 |
| Wu, P | 2 |
| Kuang, SY | 1 |
| Tang, L | 1 |
| Yang, J | 1 |
| Zhou, XQ | 1 |
| Feng, L | 1 |
| Leal, M | 1 |
| Zampini, IC | 1 |
| Mercado, MI | 1 |
| Moreno, MA | 1 |
| Simirgiotis, MJ | 1 |
| Bórquez, J | 1 |
| Ponessa, G | 1 |
| Isla, MI | 1 |
| Saliu, IO | 1 |
| Amoo, ZA | 1 |
| Khan, MF | 1 |
| Olaleye, MT | 1 |
| Rema, V | 1 |
| Akinmoladun, AC | 1 |
| Khan, AU | 1 |
| Rahman, AU | 1 |
| Yuan, Q | 1 |
| Ahmad, A | 1 |
| Khan, ZUH | 1 |
| Mahnashi, MH | 1 |
| Alyami, BA | 1 |
| Alqahtani, YS | 1 |
| Ullah, S | 1 |
| Wirman, AP | 1 |
| Gao, M | 1 |
| Deng, L | 1 |
| Zhang, K | 1 |
| Wang, M | 1 |
| Xia, Z | 1 |
| Gao, D | 1 |
| Balkissou, AD | 1 |
| Poka-Mayap, V | 1 |
| Massongo, M | 1 |
| Djenabou, A | 1 |
| Endale-Mangamba, LM | 1 |
| Olomo, EJ | 1 |
| Boulleys-Nana, JR | 1 |
| Diffo-Sonkoue, L | 1 |
| Adidigue-Ndiome, R | 1 |
| Alexandra, AJE | 1 |
| Haman-Wabi, AB | 1 |
| Adama, S | 1 |
| Iddi-Faical, A | 1 |
| Pefura-Yone, EW | 1 |
| Zhao, Q | 1 |
| Tong, W | 1 |
| Ge, C | 1 |
| Zhao, D | 1 |
| Norbäck, D | 1 |
| Li, B | 1 |
| Zhao, Z | 1 |
| Huang, C | 1 |
| Zhang, X | 1 |
| Qian, H | 1 |
| Yang, X | 1 |
| Sun, Y | 1 |
| Sundell, J | 1 |
| Deng, Q | 1 |
| Kim, HJ | 1 |
| Jeon, JW | 1 |
| Hwang, SM | 1 |
| Chu, KI | 1 |
| Cha, YH | 1 |
| Kwak, YD | 1 |
| Choi, SD | 1 |
| Aslam, M | 1 |
| Kim, CG | 1 |
| Zhou, J | 1 |
| Yang, E | 1 |
| Yang, W | 1 |
| Shi, Y | 1 |
| Yao, L | 1 |
| Fu, J | 1 |
| Xue, X | 1 |
| Knight, WD | 1 |
| Saxena, A | 1 |
| Shell, B | 1 |
| Nedungadi, TP | 1 |
| Mifflin, SW | 1 |
| Cunningham, JT | 1 |
| Stamatelopoulos, K | 1 |
| Bramos, D | 1 |
| Manios, E | 1 |
| Alexaki, E | 1 |
| Kaladaridou, A | 1 |
| Georgiopoulos, G | 1 |
| Koroboki, E | 1 |
| Kolyviras, A | 1 |
| Stellos, K | 1 |
| Zakopoulos, N | 1 |
| Toumanidis, S | 1 |
| Silveira, EA | 1 |
| Siman, FD | 1 |
| de Oliveira Faria, T | 1 |
| Vescovi, MV | 1 |
| Furieri, LB | 1 |
| Lizardo, JH | 1 |
| Stefanon, I | 1 |
| Padilha, AS | 1 |
| Vassallo, DV | 1 |
| Li, M | 1 |
| Zheng, C | 1 |
| Kawada, T | 1 |
| Inagaki, M | 1 |
| Uemura, K | 1 |
| Sugimachi, M | 1 |
| Nakane, H | 1 |
| Kamouchi, M | 1 |
| Hata, J | 1 |
| Ibayashi, S | 1 |
| Kusuda, K | 1 |
| Omae, T | 1 |
| Nagao, T | 1 |
| Ago, T | 1 |
| Kitazono, T | 1 |
| Zhang, D | 1 |
| Zheng, H | 2 |
| Muelleman, RL | 1 |
| Li, YL | 1 |
| Wang, R | 1 |
| Zhou, R | 1 |
| Dong, Z | 1 |
| Qi, Y | 1 |
| Wei, X | 1 |
| Wu, H | 1 |
| Wilcox, CS | 1 |
| Hultström, M | 1 |
| Zhou, X | 1 |
| Lai, EY | 1 |
| Sekuri, C | 1 |
| Utuk, O | 1 |
| Bayturan, O | 1 |
| Bilge, A | 1 |
| Kurhan, Z | 1 |
| Tavli, T | 1 |
| Lin, SL | 1 |
| Chen, YM | 1 |
| Chiang, WC | 1 |
| Wu, KD | 1 |
| Tsai, TJ | 1 |
| Waanders, F | 2 |
| Vaidya, VS | 1 |
| van Goor, H | 1 |
| Leuvenink, H | 1 |
| Damman, K | 1 |
| Hamming, I | 1 |
| Bonventre, JV | 1 |
| Vogt, L | 2 |
| Navis, G | 3 |
| Perico, N | 4 |
| Cattaneo, D | 1 |
| Remuzzi, G | 5 |
| Zoja, C | 1 |
| Corna, D | 1 |
| Rottoli, D | 1 |
| Gaspari, F | 1 |
| Haskell, L | 1 |
| Abe, M | 2 |
| Okada, K | 2 |
| Maruyama, T | 2 |
| Matsumoto, K | 2 |
| Plante, E | 1 |
| Lachance, D | 1 |
| Beaudoin, J | 1 |
| Champetier, S | 1 |
| Roussel, E | 1 |
| Arsenault, M | 1 |
| Couet, J | 1 |
| Soliman, SA | 1 |
| Shokeir, AA | 1 |
| Mosbah, A | 1 |
| Abol-Enein, H | 1 |
| Barakat, N | 1 |
| Abou-Bieh, E | 1 |
| Wafa, EW | 1 |
| Krum, H | 1 |
| Naito, T | 1 |
| Ma, LJ | 1 |
| Zuo, Y | 1 |
| Tang, Y | 1 |
| Han, JY | 1 |
| Kon, V | 1 |
| Fogo, AB | 1 |
| Dilauro, M | 1 |
| Zimpelmann, J | 1 |
| Robertson, SJ | 1 |
| Genest, D | 1 |
| Burns, KD | 1 |
| Suzuki, H | 3 |
| Takenaka, T | 1 |
| Thornton, SN | 1 |
| Fujihara, CK | 2 |
| Vieira, JM | 1 |
| Sena, CR | 1 |
| Ventura, BH | 1 |
| Malheiros, DM | 2 |
| Zatz, R | 2 |
| Ogino, K | 2 |
| Kato, M | 2 |
| Furuse, Y | 1 |
| Kinugasa, Y | 1 |
| Kaetsu, Y | 1 |
| Mizuta, E | 1 |
| Sugihara, S | 1 |
| Ishida, K | 1 |
| Yanagihara, K | 1 |
| Hisatome, I | 2 |
| Shigemasa, C | 2 |
| Beloborodova, AV | 1 |
| Morozova, TE | 1 |
| Shilov, EM | 1 |
| Kelland, EE | 1 |
| McAuley, LM | 1 |
| Filler, G | 1 |
| Maejima, Y | 1 |
| Nobori, K | 1 |
| Ono, Y | 1 |
| Adachi, S | 1 |
| Suzuki, J | 2 |
| Hirao, K | 1 |
| Isobe, M | 1 |
| Ito, H | 1 |
| Sanada, S | 1 |
| Komuro, I | 2 |
| Fanelli, C | 1 |
| Fernandes, BH | 1 |
| Machado, FG | 1 |
| Okabe, C | 1 |
| Colombari, DS | 1 |
| Colombari, E | 1 |
| Freiria-Oliveira, AH | 1 |
| Antunes, VR | 1 |
| Yao, ST | 1 |
| Hindmarch, C | 1 |
| Ferguson, AV | 1 |
| Fry, M | 1 |
| Murphy, D | 1 |
| Paton, JF | 1 |
| Slagman, MC | 1 |
| Nguyen, TQ | 1 |
| Hemmelder, MH | 1 |
| Laverman, GD | 2 |
| Goldschmeding, R | 1 |
| Desai, RJ | 1 |
| Ashton, CM | 1 |
| Deswal, A | 2 |
| Morgan, RO | 1 |
| Mehta, HB | 1 |
| Chen, H | 1 |
| Aparasu, RR | 1 |
| Johnson, ML | 1 |
| Milovanov, IuS | 1 |
| Kozlovskaia, LV | 1 |
| Milovanova, LIu | 1 |
| Sharma, NM | 1 |
| Mehta, PP | 1 |
| Li, YF | 1 |
| Patel, KP | 3 |
| Abadir, PM | 1 |
| Foster, DB | 1 |
| Crow, M | 1 |
| Cooke, CA | 1 |
| Rucker, JJ | 1 |
| Jain, A | 1 |
| Smith, BJ | 1 |
| Burks, TN | 1 |
| Cohn, RD | 1 |
| Fedarko, NS | 1 |
| Carey, RM | 1 |
| O'Rourke, B | 1 |
| Walston, JD | 1 |
| Fu, W | 1 |
| Liang, Y | 1 |
| Yao, W | 1 |
| Chen, W | 1 |
| Li, Q | 2 |
| Ying, PH | 1 |
| Shi, X | 1 |
| Peng, W | 1 |
| Mareev, VIu | 1 |
| Agarwal, R | 1 |
| Iseki, K | 1 |
| Takishita, S | 1 |
| Ushkvarok, LB | 1 |
| Yang, CW | 1 |
| Ahn, HJ | 1 |
| Kim, WY | 1 |
| Jung, JY | 1 |
| Yoon, SA | 1 |
| Kim, YS | 1 |
| Cha, JH | 1 |
| Bang, BK | 1 |
| Gschwend, S | 1 |
| Henning, RH | 2 |
| Pinto, YM | 1 |
| de Zeeuw, D | 2 |
| van Gilst, WH | 1 |
| Buikema, H | 1 |
| Tang, X | 1 |
| Collister, JP | 3 |
| Hendel, MD | 2 |
| Simko, F | 1 |
| Simko, J | 1 |
| Fabryova, M | 1 |
| Kinugawa, T | 1 |
| Osaki, S | 1 |
| Igawa, O | 1 |
| Uresin, Y | 1 |
| Erbas, B | 1 |
| Ozek, M | 1 |
| Ozkök, E | 1 |
| Gürol, AO | 1 |
| Mas, VR | 1 |
| Alvarellos, T | 1 |
| Maluf, DG | 1 |
| Ferreira-Gonzalez, A | 1 |
| Oliveros, L | 1 |
| Maldonado, RA | 1 |
| de Boccardo, G | 1 |
| Machackova, J | 1 |
| Lukas, A | 1 |
| Dhalla, NS | 1 |
| Zhu, GQ | 1 |
| Gao, L | 2 |
| Zucker, IH | 3 |
| Wang, W | 2 |
| Guan, J | 1 |
| Cheng, DY | 1 |
| Chen, XJ | 1 |
| Su, QL | 1 |
| Ueland, T | 1 |
| Aukrust, P | 1 |
| Yndestad, A | 1 |
| Otterdal, K | 1 |
| Frøland, SS | 1 |
| Dickstein, K | 2 |
| Kjekshus, J | 2 |
| Gullestad, L | 1 |
| Damås, JK | 1 |
| Renke, M | 1 |
| Tylicki, L | 1 |
| Rutkowski, P | 1 |
| Rutkowski, B | 1 |
| Schultz, HD | 1 |
| Osborn, JW | 1 |
| Wolf, G | 1 |
| Butorov, IV | 1 |
| Butorov, SI | 1 |
| Coto, E | 1 |
| Marín, R | 1 |
| Alvarez, V | 1 |
| Praga, M | 1 |
| Fernández Andrade, C | 1 |
| Arias, M | 1 |
| Poveda, R | 1 |
| Vallés, M | 1 |
| Galcerán, JM | 1 |
| Luño, J | 1 |
| Rivera, F | 2 |
| Campistol, JM | 2 |
| Barrios Alonso, V | 1 |
| Escobar Cervantes, C | 1 |
| Calderón Montero, A | 1 |
| Shoda, J | 1 |
| Kanno, Y | 1 |
| Ruggenenti, P | 1 |
| Zoccal, DB | 1 |
| Bonagamba, LG | 1 |
| Oliveira, FR | 1 |
| Antunes-Rodrigues, J | 1 |
| Machado, BH | 1 |
| Tarsitano, CA | 1 |
| Paffaro, VA | 1 |
| Pauli, JR | 1 |
| da Silva, GH | 1 |
| Saad, MJ | 1 |
| Salgado, I | 1 |
| da Cruz-Höfling, MA | 1 |
| Hyslop, S | 1 |
| Rysä, J | 1 |
| Aro, J | 1 |
| Ruskoaho, H | 1 |
| Kudo, Y | 1 |
| Akazawa, H | 1 |
| Ramasubbu, K | 1 |
| Tiurenkov, IN | 1 |
| Nazvanova, AN | 1 |
| Tchepurina, NG | 1 |
| Kheyfets, IA | 1 |
| Dugina, JL | 1 |
| Martyushev-Poklad, AV | 1 |
| Sergeeva, SA | 1 |
| Epstein, OI | 1 |
| Chang, P | 1 |
| Willenheimer, R | 1 |
| Haunsø, S | 1 |
| Remes, J | 1 |
| Hall, C | 1 |
| van der Mark, J | 1 |
| Kline, RL | 1 |
| Dale, WE | 1 |
| Hasser, EM | 1 |
| Blaine, EH | 1 |
| Cervenka, L | 1 |
| Heller, J | 1 |
| Jelínek, F | 1 |
| Locatelli, F | 1 |
| Sigmon, DH | 1 |
| Beierwaltes, WH | 1 |
| dos Santos, CM | 1 |
| Moreira, ED | 2 |
| Krieger, EM | 2 |
| Michelini, LC | 1 |
| Cottone, S | 1 |
| Vadalà, A | 1 |
| Vella, MC | 1 |
| Nardi, E | 1 |
| Mulé, G | 1 |
| Contorno, A | 1 |
| Riccobene, R | 1 |
| Cerasola, G | 1 |
| Camara, AK | 1 |
| Osborn, JL | 1 |
| Amuchastegui, SC | 1 |
| Azzollini, N | 2 |
| Mister, M | 2 |
| Pezzotta, A | 2 |
| Fang, TC | 1 |
| Huang, WC | 1 |
| Liu, JL | 1 |
| Jones, RE | 1 |
| Ball, EV | 1 |
| Kutyrina, IM | 1 |
| Tareeva, IE | 1 |
| Nosikov, VV | 1 |
| Kamyshova, ES | 1 |
| Gorashko, NM | 1 |
| Chistiakov, DA | 1 |
| Okonova, EB | 1 |
| Troepol'skaia, OV | 1 |
| Koval', SN | 1 |
| Belovol, AN | 1 |
| Miloslavskiĭ, DK | 1 |
| Masliaeva, LV | 1 |
| Mysnichenko, OV | 1 |
| Iñigo, P | 1 |
| Jimenez, W | 1 |
| Lario, S | 1 |
| Clesca, PH | 1 |
| Oppenheimer, F | 1 |
| Fletcher, EC | 1 |
| Bao, G | 1 |
| Li, R | 1 |
| Rodríguez-García, JL | 1 |
| Paule, A | 1 |
| Domínguez, J | 1 |
| García-Escribano, JR | 1 |
| Vázquez, M | 1 |
| Ohta, H | 1 |
| Satomi, T | 1 |
| Ikemoto, F | 1 |
| Nishikibe, M | 1 |
| Houghton, AR | 1 |
| Harrison, M | 1 |
| Cowley, AJ | 1 |
| Henger, A | 1 |
| Tutt, P | 1 |
| Riesen, WF | 1 |
| Hulter, HN | 1 |
| Krapf, R | 1 |
| Farah, VM | 1 |
| Ushizima, M | 1 |
| Cestari, IA | 1 |
| Irigoyen, MC | 1 |
| Leung, PS | 1 |
| Lam, SY | 1 |
| Fung, ML | 1 |
| Porcu, M | 1 |
| Orrù, P | 1 |
| Leenen, FH | 1 |
| Berry, C | 1 |
| Norrie, J | 1 |
| McMurray, JJ | 1 |
| Jamali, AH | 1 |
| Tang, WH | 1 |
| Khot, UN | 1 |
| Fowler, MB | 1 |
| Noris, M | 1 |
| Benigni, A | 1 |
| Marchetti, G | 1 |
| Gagliardini, E | 1 |
| Würzner, G | 1 |
| Gerster, JC | 1 |
| Chiolero, A | 1 |
| Maillard, M | 1 |
| Fallab-Stubi, CL | 1 |
| Brunner, HR | 1 |
| Burnier, M | 1 |
| de Jong, PE | 1 |
| Komajda, M | 1 |
| Suga, S | 1 |
| Mazzali, M | 1 |
| Ray, PE | 1 |
| Kang, DH | 1 |
| Johnson, RJ | 1 |
| Xiu, JC | 1 |
| Xu, JP | 1 |
| Guo, Z | 1 |
| Lai, W | 1 |
| Li, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Losartan Improved Insulin Resistance and Decreased Inflammatory Cytokines in Patients With Chronic Heart Failure Treated With Angiotensin Converting Enzyme Inhibitors[NCT00663377] | Phase 4 | 16 participants (Anticipated) | Interventional | 2006-04-30 | Completed | ||
| DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease[NCT02875886] | Phase 4 | 28 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Study of Muscle Strength Maintenance in Older Adults[NCT01989793] | Phase 2 | 37 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity[NCT02896309] | 45 participants (Actual) | Interventional | 2016-09-30 | Completed | |||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 16 (i.e., baseline minus week 16) was the outcome of the analysis. A negative number indicates decrease in strength from week 0 to week 16." (NCT01989793)
Timeframe: Baseline to Week 16
| Intervention | Newton (Mean) |
|---|---|
| Losartan | -7.40 |
| Placebo | -4.27 |
"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 24 (i.e., baseline minus week 24) was the outcome of the analysis. A negative number indicates a decrease in strength from week 0 to week 24." (NCT01989793)
Timeframe: Baseline to Week 24
| Intervention | Newton (Mean) |
|---|---|
| Losartan | -9.20 |
| Placebo | -7.00 |
"Isokinetic Strength was measured by knee extension exercises where bilateral knee concentric strength was measured using a Biodex System 3 dynamometer set at an angular velocity of 30deg/sec through a joint arc from 90 degrees to 30 degrees (0 degrees- full extension).~The change in strength between baseline and week 8 (i.e., baseline minus week 8) was the outcome of the analysis. A negative number indicates that there was a decrease in isokinetic strength from week 0 to week 8." (NCT01989793)
Timeframe: Baseline to Week 8
| Intervention | Newton (Mean) |
|---|---|
| Losartan | -4.90 |
| Placebo | -4.73 |
"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to that of the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 16
| Intervention | percentage of work (Mean) |
|---|---|
| Losartan | 16.51 |
| Placebo | 8.77 |
"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to that of the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 24
| Intervention | percentage of work (Mean) |
|---|---|
| Losartan | 17.07 |
| Placebo | 9.05 |
"Fatiguability was tested using bilateral knee extension with an external load equal to 40% of the maximal voluntary contraction force.~Fatiguability was defined as the ratio (expressed as a percentage) of the total work in the last 3 of the 10 repetitions to the total work in the first 3 of the 10 repetitions, where the total work for n repetitions is defined as the sum of peak torque (FT-LBS) over n repetitions (i.e., last three reps/first three reps). The maximum of the two sides was used in the analysis." (NCT01989793)
Timeframe: Week 8
| Intervention | percentage of work (Mean) |
|---|---|
| Losartan | 14.29 |
| Placebo | 7.87 |
Number of participants experiencing any amount of decrease in frailty score from baseline to Week 16 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 3 |
| Placebo | 5 |
Number of participants experiencing any amount of decrease in frailty score from baseline to Week 24 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 3 |
| Placebo | 5 |
Number of participants experiencing any amount of decrease in frailty score from baseline to Week 8 (i.e., improvement in frailty status) (NCT01989793)
Timeframe: from baseline to 8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Losartan | 3 |
| Placebo | 6 |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
11 reviews available for losartan and Chronic Illness
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
[Recent clinical evidences of RAS inhibitors on chronic kidney diseases].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimida | 2010 |
[The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys].
Topics: Angiotensin II Type 1 Receptor Blockers; Calcitriol; Cardiovascular Diseases; Chronic Disease; Ergoc | 2011 |
Angiotensin type 1 receptor blockers in chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Clinical Trials as Topic; Diabetic Nephrop | 2004 |
[The renin-angiotensin-aldosterone system -- more complex as previously thought].
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2005 |
[ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart | 2005 |
Time to abandon microalbuminuria?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2006 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
Anti-angiotensin therapy: new perspectives.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; | 2007 |
[Pharmacological characteristics and clinical application of losartan, an orally active AT1 angiotensin II receptor antagonist].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Chronic Disease; Clinical Trials | 1999 |
The role of angiotensin receptor blockers in the management of chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bradykin | 2001 |
23 trials available for losartan and Chronic Illness
| Article | Year |
|---|---|
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; | 2022 |
Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2008 |
Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.
Topics: Acetylglucosaminidase; Adult; Aged; Antihypertensive Agents; Biomarkers; Chronic Disease; Combined M | 2009 |
Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2009 |
Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Chronic Disease; Creatinine; Dose-Response Relationsh | 2009 |
Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without β-blockers.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E | 2010 |
[An experience of the use of angiotensin II receptor blocker losartan in patients with metabolic syndrome and chronic kidney disease].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Blood Pressure | 2010 |
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
Topics: Aged; Angiotensin Receptor Antagonists; Chronic Disease; Drug Synergism; Drug Therapy, Combination; | 2011 |
Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chronic Disease; Combined Modality Therapy; Con | 2011 |
Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2003 |
[Serum TIMP-1 concentration in patients with chronic glomerulonephritis and the effect of losartan].
Topics: Adolescent; Adult; Chronic Disease; Female; Fibrosis; Glomerulonephritis; Humans; Kidney; Losartan; | 2003 |
Effects of angiotensin II type 1 receptor antagonist, losartan, on ventilatory response to exercise and neurohormonal profiles in patients with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Humans; Hyperventil | 2004 |
Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Humans; Kidney; Kidney Dise | 2004 |
Soluble CD40 ligand in acute and chronic heart failure.
Topics: Acute Disease; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2005 |
Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Topics: Adult; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2004 |
A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Ben | 2006 |
Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Diseas | 1995 |
[Neurohumoral changes in patients with mild and moderate forms of hypertension under the influence of losartan].
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chronic Disease; Female; Hemodynam | 1999 |
Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Blood Pressure; Chronic Disease; Endothelins; | 1999 |
Haemodynamic, neurohumoral and exercise effects of losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Evaluation of Losartan in the Elderly.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic | 1999 |
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
Topics: Aged; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cross-Over Studies; Double-Blind | 2001 |
Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.
Topics: Antihypertensive Agents; Chronic Disease; Dose-Response Relationship, Drug; Humans; Losartan; Prospe | 2001 |
70 other studies available for losartan and Chronic Illness
| Article | Year |
|---|---|
Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system.
Topics: Amides; Animals; Blood Pressure; Chronic Disease; Extracellular Matrix; Female; Fumarates; Losartan; | 2017 |
Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Pressure; Autonomic Nervous System; Brain | 2013 |
Pleiotropic effects of the acute and chronic inhibition of the renin-angiotensin system in hypertensives.
Topics: Acute Disease; Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Case-Control S | 2014 |
Low-dose chronic lead exposure increases systolic arterial pressure and vascular reactivity of rat aortas.
Topics: Acetophenones; Animals; Antioxidants; Aorta; Blood Pressure; Chronic Disease; Cyclooxygenase 2 Inhib | 2014 |
Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long-term survival in rats with chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cholinesterase Inhibitors; Chronic Disease; Diseas | 2014 |
Effect of angiotensin II on voltage-gated sodium currents in aortic baroreceptor neurons and arterial baroreflex sensitivity in heart failure rats.
Topics: Angiotensin II; Animals; Aorta; Arteries; Baroreflex; Chronic Disease; Disease Models, Animal; Heart | 2015 |
Sympathoexcitation in Rats With Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus.
Topics: 3' Untranslated Regions; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding S | 2016 |
Effect of losartan on exercise tolerance and echocardiographic parameters in patients with mitral regurgitation.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Electrocardiography; Exercise | 2008 |
Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression.
Topics: Animals; Antihypertensive Agents; Biomarkers; Chronic Disease; Disease Models, Animal; Disease Progr | 2009 |
V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antidiur | 2009 |
Comparative study of vasodilators in an animal model of chronic volume overload caused by severe aortic regurgitation.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic V | 2009 |
Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chronic Disease; Dogs; Kidney Diseases; Losartan; | 2010 |
Optimising management of chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chroni | 2009 |
Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2010 |
Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease.
Topics: Albuminuria; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2010 |
RAAS blockade in combination with diuretic therapy increases urine excretion, which in turn increases drinking and thus reduces erythropoietin and proteinuria.
Topics: Chronic Disease; Diuretics; Drinking Behavior; Drug Therapy, Combination; Erythropoietin; Hemodiluti | 2010 |
Early brief treatment with losartan plus mycophenolate mofetil provides lasting renoprotection in a renal ablation model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Press | 2010 |
Are we ready to use aliskiren in children?
Topics: Adolescent; Age Factors; Amides; Angiotensin II Type 1 Receptor Blockers; Child, Preschool; Chronic | 2011 |
Costarring statins with ARBs: going to be a smash hit?
Topics: Angiotensin Receptor Antagonists; Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; | 2011 |
Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Blood Pressure; | 2011 |
Switching control of sympathetic activity from forebrain to hindbrain in chronic dehydration.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Chronic Disease; Dehydration; Hypothalamus; Losart | 2011 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confoun | 2012 |
Decreased nNOS in the PVN leads to increased sympathoexcitation in chronic heart failure: role for CAPON and Ang II.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Anima | 2011 |
Identification and characterization of a functional mitochondrial angiotensin system.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Autocrine Communication; Cell Line; Chronic | 2011 |
Renal microvascular injury in chronic aristolochic acid nephropathy and protective effects of Cozaar.
Topics: Animals; Aristolochic Acids; Chronic Disease; Kidney; Kidney Diseases; Losartan; Male; Microvessels; | 2012 |
[Is it real to replace angiotensin converting enzyme inhibitors as basic remedy in the treatment of chronic heart failure?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Clinical Trials as Topic; Dose | 2002 |
Progression of renal failure delayed by use of losartan in a case of IgA nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chronic Disease; Creatinine; Disea | 2002 |
[Stability of neurohumoral effects of losartan combined with metoprolol in chronic cardiac low output].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Cardiac Output, Low; Chronic Disease; | 2002 |
Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arterioles; Blood Pressure; Body Weight; Chronic D | 2003 |
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2003 |
The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Chronic Disease; Dr | 2003 |
ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; | 2003 |
Subfornical organ lesion attenuates chronic hypotensive effects of losartan in salt-replete rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Body Wate | 2003 |
Losartan may prevent the elevation of plasma glucose, corticosterone and catecholamine levels induced by chronic stress.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Chronic Disease; Corticosterone; Epinephrine; Hyper | 2004 |
Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic | 2004 |
ANG II in the paraventricular nucleus potentiates the cardiac sympathetic afferent reflex in rats with heart failure.
Topics: Angiotensin II; Animals; Arteries; Cardiac Output, Low; Chronic Disease; Coronary Vessels; Dose-Resp | 2004 |
[The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chronic Disease; Collagen; Hypertension, Pulmonary | 2004 |
Augmented input from cardiac sympathetic afferents inhibits baroreflex in rats with heart failure.
Topics: Animals; Antihypertensive Agents; Arteries; Baroreflex; Capsaicin; Cardiac Output, Low; Chronic Dise | 2005 |
Role of a responsive sympathetic nervous system in the chronic hypotensive effects of losartan in normal rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Chronic Disease; Ganglionic Blocke | 2005 |
[Use of lozartan in patients with chronic cor pulmonale].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Gas Analysis; Chronic Disease; Ery | 2005 |
[Pharmacogenetics of angiotensin system in non diabetic nephropathy].
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel | 2005 |
Increased sympathetic activity in rats submitted to chronic intermittent hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Chronic Disease; Disease Models, A | 2007 |
Hepatic morphological alterations, glycogen content and cytochrome P450 activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Chronic | 2007 |
Early left ventricular gene expression profile in response to increase in blood pressure.
Topics: Acute Disease; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Ag | 2006 |
Comparison of the cardioprotective effects of cardos and losartan in rats with experimental chronic cardiac insufficiency.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies; Cardiotonic Agents; Chronic Disease; D | 2007 |
Altered pressure natriuresis in chronic angiotensin II hypertension in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Chron | 1994 |
Acute and chronic angiotensin hypertension: neural and nonneural components, time course, and dose dependency.
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; B | 1996 |
Lack of a beneficial effect of PD123319, an AT2-angiotensin receptor antagonist, on the course of ablation nephropathy in the rat.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressu | 1996 |
Antiproteinuric effect of losartan in patients with chronic renal diseases.
Topics: Chronic Disease; Humans; Kidney Diseases; Losartan; Proteinuria | 1997 |
Influence of nitric oxide in the chronic phase of two-kidney, one clip renovascular hypertension.
Topics: Animals; Antihypertensive Agents; Chronic Disease; Enzyme Inhibitors; Hemodynamics; Hypertension, Re | 1998 |
Chronic AT1 receptor blockade alters aortic nerve activity in hypertension.
Topics: Afferent Pathways; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Blood | 1998 |
Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Chronic Disease; Endothelins; Fema | 1998 |
AT1 receptors mediate chronic central nervous system AII hypertension in rats fed high sodium chloride diet from weaning.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; | 1998 |
Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism.
Topics: Analysis of Variance; Animals; Calcium Channel Blockers; Chronic Disease; Dihydropyridines; Disease | 1998 |
Role of angiotensin II in hyperinsulinemia-induced hypertension in rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pr | 1998 |
Regulation of sympathetic nerve activity in heart failure: a role for nitric oxide and angiotensin II.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output, Low; Cardiac Pacin | 1999 |
Gout: beyond the stereotype.
Topics: Aged; Algorithms; Allopurinol; Chronic Disease; Diagnosis, Differential; Female; Gout; Gout Suppress | 1999 |
[Polymorphism studies of angiotensin converting enzyme gene in chronic glomerulonephritis].
Topics: Adolescent; Adult; Alleles; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 1999 |
Renin activity and blood pressure in response to chronic episodic hypoxia.
Topics: Adrenal Medulla; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Chem | 1999 |
Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin II; Antihypertensive Agents; Blood Pressure; Chronic Disease; C | 1999 |
Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients.
Topics: Acid-Base Equilibrium; Acidosis; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Chronic D | 2000 |
Acute AT1 receptor blockade does not improve the depressed baroreflex in rats with chronic renal hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Baroreflex; Brad | 2000 |
Chronic hypoxia upregulates the expression and function of AT(1) receptor in rat carotid body.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Carotid Body; Chemoreceptor Cells; Chroni | 2000 |
[Current role of angiotensin II antagonists in the treatment of heart failure].
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Clinical Trials as Topic; Drug | 2000 |
AT(1) receptor blockers prevent sympathetic hyperactivity and hypertension by chronic ouabain and hypertonic saline.
Topics: Air Movements; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; B | 2001 |
Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2. Evaluation of Losartan In The Elderly.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cause o | 2001 |
Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Chronic Disease; Creatinine; Cyclosporine | 2001 |
Are angiotensin II receptor blockers indicated in chronic heart failure?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disea | 2002 |
Angiotensin II type 1 receptor blockade ameliorates tubulointerstitial injury induced by chronic potassium deficiency.
Topics: Angiotensin Receptor Antagonists; Animals; Arginine; Chronic Disease; Dinoprostone; Kidney; Losartan | 2002 |
Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; | 2002 |